A novel antibody-drug conjugate (ADC) for adults with refractory or relapsing diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, has received accelerated FDA approval. Up to 40% of patients with DLBCL will relapse.
Polatuzumab vedotin is indicated for patients whose DLBCL has progressed or returned after at least 2 previous therapies. It is intended for use in combination with the standard chemotherapy regimen bendamustine plus rituximab (BR).
Sancar F. Chemoimmunotherapy for Lymphoma. JAMA. 2019;322(3):199. doi:10.1001/jama.2019.9918
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: